ReviewThe journal of allergy and clinical immunology. In practice
Allergic bronchopulmonary aspergillosis.
Review in The journal of allergy and clinical immunology. In practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 163 citations in OpenAlex.
- Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses.The European respiratory journal · 2024Guideline
- Comparison of diagnostic efficiency of detecting IgG and IgE with immunoassay method in diagnosing ABPA: a meta-analysis.BMC pulmonary medicine · 2023Pooled it
- High total serum IgE level at diagnosis was associated with a progressive decline in lung function in asthmatic patients with allergic bronchopulmonary mycosis.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026Article
- Deciphering the toxicological mechanism of airway allergic diseases caused by dioctyl terephthalate: a composite study.Frontiers in toxicology · 2026Article
- Clinical Characteristics of Difficult-To-Treat Allergic Bronchopulmonary Aspergillosis and Its Prediction Score.Allergy · 2025Article
- Indoor and Outdoor Fungal Allergens and Impacts on Respiratory Allergic Disease.The journal of allergy and clinical immunology. In practice · 2025Review
- T1-T2 Interplay in the Complex Immune Landscape of Severe Asthma.Immunological reviews · 2025Review
- Treatment of allergic bronchopulmonary aspergillosis with biologics.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Hyper IgE Syndromes: Understanding, Management, and Future Perspectives: A Narrative Review.Health science reports · 2025Article
- Allergic bronchopulmonary aspergillosis with metachronous isolation of three distinctRespirology case reports · 2024Article
- Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations.Pathophysiology : the official journal of the International Society for Pathophysiology · 2024Review
- Amphotericin B in the Era of New Antifungals: Where Will It Stand?Journal of fungi (Basel, Switzerland) · 2024Review
- Risk factors for short-term prognosis of end-stage liver disease complicated by invasive pulmonary aspergillosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Exploring the immunopathology of type 2 inflammatory airway diseases.Frontiers in immunology · 2024Review
- Article
- Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals.Journal of fungi (Basel, Switzerland) · 2023Article
- Type 2 inflammation in asthma and other airway diseases.ERJ open research · 2022Review
- Article
- Use of Intravenous Pulse Steroids to Treat Allergic Bronchopulmonary Aspergillosis in a Non-Compliant Asthmatic Adolescent.Children (Basel, Switzerland) · 2022Article
- The Role of Comorbidities in Difficult-to-Control Asthma in Adults and Children.The journal of allergy and clinical immunology. In practice · 2022Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
There remains a lack of agreement on diagnostic criteria and approaches to treatment of patients with allergic bronchopulmonary aspergillosis (ABPA). The results of a survey of American Academy of Allergy, Asthma, & Immunology members regarding these 2 issues are presented and compared for concordance with published recommendations. The literature was reviewed for pertinent reports, and an electronic survey was conducted of American Academy of Allergy, Asthma, & Immunology members and fellows regarding diagnostic criteria, numbers of patients evaluated for ABPA, and treatment approaches. From 508 respondents to the survey sent to 5155 US physicians in the American Academy of Allergy, Asthma, & Immunology database of members and fellows, 245 health professionals (48%) had treated at least 1 patient with ABPA in the previous year. For the diagnosis of ABPA, there was a difference in the threshold concentration of total serum IgE because 44.9% used ≥417 kU/L, whereas 42.0% used ≥1000 kU/L. Analysis of these findings suggests that ABPA might be underdiagnosed. With regard to pharmacotherapy, oral steroids were recommended for 97.1% of patients and oral steroids plus inhaled corticosteroids plus antifungal agent were used with 41.2% of patients. The armamentarium for treatment of ABPA includes oral corticosteroids as the initial treatment with inhaled corticosteroids used for management of persistent asthma. Azoles remain adjunctive. Published experience with omalizumab has been limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.